Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Thymitaq (Zarix).

I Niculescu-Duvaz¹

¹ion@icr.ac.uk

Current Opinion in Investigational Drugs (London, England : 2000)

|September 25, 2001

Summary

This summary is machine-generated.

Zarix is developing Thymitaq (nolatrexed dihydrochloride) for unresectable hepatocellular carcinoma (HCC). Phase III trials show Thymitaq offers improved survival and disease stabilization compared to doxorubicin, with manageable side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Same author

Development of an outpatient finger-prick glomerular filtration rate procedure suitable for epidemiological studies.

Kidney international·2006

Same author

NCI-EORTC-AACR--11th Symposium on New Drugs in Cancer Therapy: Gene therapy and new drugs. 7-10 November 2000, Amsterdam, The Netherlands.

IDrugs : the investigational drugs journal·2005

Same author

Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems.

Journal of medicinal chemistry·2004

Same author

Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer.

Current opinion in molecular therapeutics·2001

Same author

Definition of chromosome aberrations in testicular germ cell tumor cell lines by 24-color karyotyping and complementary molecular cytogenetic analyses.

Cancer genetics and cytogenetics·2001

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

Area of Science:

Oncology
Pharmacology
Clinical Trials

Background:

Thymitaq (nolatrexed dihydrochloride) is an investigational cancer therapeutic.
Previous development by Agouron was discontinued due to insufficient differentiation from existing treatments.
Zarix acquired rights and focused development on unresectable hepatocellular carcinoma (HCC).

Purpose of the Study:

To evaluate the efficacy and safety of Thymitaq in patients with unresectable HCC.
To compare Thymitaq against doxorubicin in a Phase III clinical trial.

Main Methods:

A multicenter, multinational Phase III clinical trial comparing Thymitaq to doxorubicin.
Patient enrollment across approximately 50 sites in the US, Canada, Europe, and South Africa.
Intent-to-treat survival analysis and assessment of disease stabilization.

Related Experiment Videos

Main Results:

Thymitaq demonstrated improved median survival (over 23 weeks) compared to doxorubicin (less than 15 weeks) in Phase II trials.
A majority of patients achieved disease stabilization with Thymitaq treatment.
Thymitaq exhibits no end-organ toxicity, with side effects typical of antimetabolites but of shorter duration.

Conclusions:

Thymitaq shows promise as a treatment for unresectable HCC, offering survival benefits and disease control.
The drug's favorable safety profile supports its potential as a therapeutic option.
Further development and regulatory filing are planned based on positive trial outcomes.